Havana, Cuba: Cuba’s Abdala vaccine showed 100 percent efficacy in its phase III clinical trials to prevent severe systemic disease and death from Covid-19, its developers announced today.
This immunizer, the first in Latin America and developed by the Island’s Center for Genetic Engineering and Biotechnology (CIGB), had already shown 92.28 percent efficacy against the symptomatic disease.
‘There are already clinical efficacy data from the phase III trial of Abdala with excellent results, and at the moment it is scaled to an effectiveness study with more than 300 thousand people. Vaccines need us?, Dr. Marta Ayala, director of the CIGB, told Cubadebate.